Makers Laboratories Ltd Upgraded to Hold on Technical Improvements and Mixed Financial Signals

Technical Indicators Drive Upgrade

The primary catalyst behind the upgrade to a Hold rating is the marked improvement in Makers Laboratories’ technical profile. The technical grade shifted from mildly bullish to bullish, signalling stronger market momentum. Key technical indicators underpinning this change include a bullish Moving Average on the daily chart and positive signals from the weekly MACD and Bollinger Bands. Specifically, the weekly MACD is bullish while the monthly MACD remains mildly bullish, suggesting sustained upward momentum in the near term.

Other technical metrics present a mixed but generally positive picture. The weekly KST (Know Sure Thing) indicator is bullish, although the monthly KST remains bearish, indicating some caution over longer-term momentum. The Relative Strength Index (RSI) on both weekly and monthly timeframes shows no clear signal, while the Dow Theory assessment is mildly bearish weekly and neutral monthly. Overall, the technical landscape supports a cautiously optimistic stance, justifying the upgrade from Sell to Hold.

On the price front, Makers Laboratories closed at ₹151.45, up 2.78% from the previous close of ₹147.35. The stock traded within a range of ₹149.15 to ₹163.00 during the session, remaining comfortably above its 52-week low of ₹109.00 but still below the 52-week high of ₹173.70. This price action aligns with the bullish technical signals and suggests potential for further gains.

Financial Trend Shows Recent Strength Amid Long-Term Challenges

Financially, Makers Laboratories has delivered encouraging quarterly results for Q3 FY25-26, which have contributed to the improved outlook. The company reported its highest-ever quarterly net sales of ₹35.67 crores and a PBDIT of ₹4.16 crores, marking a significant operational milestone. The operating profit margin to net sales also reached a peak of 11.66%, underscoring improved efficiency and cost management during the quarter.

However, the longer-term financial trend remains a concern. Over the past five years, the company’s operating profits have declined at a compounded annual growth rate (CAGR) of -15.78%, reflecting structural challenges in sustaining profitability. Additionally, the average Return on Equity (ROE) stands at a modest 2.20%, indicating limited profitability relative to shareholders’ funds. The most recent annual figures reveal a sharp 82.7% drop in profits despite a 13.02% stock return over the same period, highlighting a disconnect between market performance and underlying earnings.

Valuation Remains Expensive Despite Weak Fundamentals

Makers Laboratories is currently classified as a micro-cap stock with a Price to Book (P/B) ratio of 1.3, which is considered very expensive relative to its peers and historical averages. This premium valuation is not fully supported by the company’s fundamentals, especially given the weak long-term profit growth and low ROE. The stock’s elevated valuation suggests that investors are pricing in expectations of a turnaround or improved future performance, which remains to be realised.

Comparatively, the stock’s returns have outpaced the Sensex over multiple time horizons. For instance, the stock has delivered a 28.18% year-to-date return versus a Sensex decline of 8.52%, and a 40.49% return over three years compared to the Sensex’s 27.69%. However, over a five-year period, Makers Laboratories underperformed significantly with a -36.90% return against the Sensex’s 59.26% gain. This mixed performance underscores the stock’s volatility and the importance of cautious valuation assessment.

Quality Assessment and Shareholding Structure

The company’s quality rating remains moderate, reflected in its Mojo Score of 50.0 and a current Mojo Grade of Hold, upgraded from Sell on 6 May 2026. The pharmaceutical and biotechnology sector is highly competitive and capital intensive, and Makers Laboratories faces challenges in scaling profitability. The majority shareholding remains with promoters, which can be a double-edged sword—providing stability but also concentration risk.

Technical Momentum and Market Context

The upgrade also reflects the stock’s recent price momentum relative to the broader market. Over the past week, Makers Laboratories surged 7.03%, significantly outperforming the Sensex’s 0.60% gain. Although the one-month return of 2.54% trails the Sensex’s 5.20%, the year-to-date and one-year returns remain robust at 28.18% and 13.02%, respectively. This relative strength has attracted technical buying interest, reinforcing the bullish signals from moving averages and momentum oscillators.

Despite these gains, the stock remains below its 52-week high of ₹173.70, suggesting room for upside if the company can sustain operational improvements and market sentiment remains favourable. Investors should weigh the technical optimism against the company’s expensive valuation and weak long-term fundamentals before committing fresh capital.

Conclusion: A Cautious Hold with Upside Potential

The upgrade of Makers Laboratories Ltd from Sell to Hold by MarketsMOJO reflects a nuanced view balancing recent technical strength and quarterly financial improvements against persistent valuation and fundamental challenges. The bullish technical indicators and positive quarterly sales and profit margins provide a foundation for cautious optimism. However, the company’s weak five-year profit growth, low ROE, and premium valuation warrant a conservative stance.

Investors should monitor upcoming quarterly results and sector developments closely, as sustained operational momentum and improved profitability could justify further upgrades. Until then, the Hold rating signals that Makers Laboratories is a stock to watch rather than aggressively accumulate, especially given the availability of potentially superior alternatives within the Pharmaceuticals & Biotechnology sector.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →